吴小津  

擅长疾病：恶性血液病，再生障碍性贫血，淋巴瘤等各种血液病造血干细胞移植

个人简介：自2004年研究生毕业后一直从事血液临床工作，目前是主任医师，教授，博导，主要擅长各种血液病造血干细胞移植理，目前主要从事恶性造血干细胞移植临床和免疫机制研究，及其血液病相关的免疫机制研究。2009年和2017年在美国Scripps研究所和俄亥俄州州立大学肿瘤综合治疗中心进修学习。目前为江苏省江苏333工程二层次人才，六大高峰人才，苏州大学博习创新领军人才。

科研情况：主要从事造血干细胞移植临床研究，致力于难治复发恶性血液病和高致敏患者异基因造血干细胞移植方案的优化，移植后并发症预防方案的优化和临床大队列预测模型的建立和移植后感染免疫机制研究。近五年平均每年独立完成异基因造血干细胞移植手术200例，累积完成超过1000例。同时也致力于恶性血液病免疫机制，探索急性白血病患者免疫图谱的时空改变和靶向免疫治疗的机制，同时以通讯作者和第一作者发表中华核心及其SCI论文100余篇，累积影响因子超过500分。获得国家自然科学基金，江苏省自然科学，国家重点研发，苏州市重大专病多项基金等资助。

学术任职：

国家教育部临床博士学位点评审专家
中华医学会血液学分会（白血病淋巴瘤学组）委员
血液病数字诊疗专委会常委
中国医药教育协会感染专业委员会（IDSC)委员
全国微移植和细胞治疗组委员
中国输血协会细胞治疗专业委员
中华抗癌协会血液病转化委员会青年委员
江苏省与苏州市血液病医疗质控中心委员
苏州市老年血液病学组副组长
国家自然科学基金项目评审专家
Stem cell Research&Therapy、Cell Transplantation、Hematology、Frontiers in Oncology、Frontiers in Immunology、Signal Transduction and Targeted Therapy 等杂志审稿人等

教育背景（从大学本科开始，按时间倒序排序）：

• 2008.9–2011.6, 苏州大学, 内科（血液学）, 博士, 导师: 吴德沛
• 2001.9–2004.6, 苏州大学, 内科（血液学）, 硕士, 导师: 吴德沛
• 1996.9–2001.6, 苏州医学院, 临床医学, 学士, 导师: 无

科研与学术工作经历（按时间倒序排序）：

• 2019.12-至今 苏州大学, 附属第一医院, 主任医师，教授
• 2014.7-2019.11, 苏州大学, 附属第一医院, 副主任医师，副教授
• 2009.8-2014.6, 苏州大学, 附属第一医院, 讲师
• 2004.8-2009.7, 苏州大学, 附属第一医院, 助教

研究领域

主要研究方向为：(1) 造血干细胞移植及其免疫机制；(2) 免疫缺陷血液病患者重度感染的微生态与代谢组学机制和预测模型建立；(3) 急性白血病患者免疫衰竭机制研究。

取得研究成果和获得学术奖励情况

【主要代表论文】（#共同第一作者和*通讯作者）
1. Tingting Zhang #, Yuqi Zhang #, Meijia Zhou #, Zhibo Zhang, Xiebing Bao, Lijun Wen, Yufeng Feng, Xiaobo Li, Mingya Zhai, Xiangjun Liu, Zhao Zeng, Xiaojin Wu*, Suning Chen*. (2024). Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation. British journal of haematology, 10.1111/bjh.19304. Advance online publication. IF=6.501
2. Lu Gao #, Li Yang #, Shiyuan Zhou, Wenjuan Zhu, Yue Han, Suning Chen, Shengli Xue, Ying Wang, Huiying Qiu*, Depei Wu*, Xiaojin Wu*. (2024). Allogenic hematopoietic stem cell transplantation outcomes of patients aged?≥?55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study. Stem cell research & therapy, 15(1), 24. IF=7.500
3. Xiaojin Wu, Xiao Ma, Tiemei Song, Jie Liu, Yi Sun, Depei Wu*. (2024). The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping. Annals of hematology, 103(3), 917–933. IF=3.5
4.Yu-Qi Zhang #, Wen-Qi Wu #, Jie Xu, Zai-Xiang Tang, Shi-Jia Li, Ling Li, He-Qing Wu, Xiao Ma, Ji-Sheng Liu, De-Pei Wu*, Xiao-Jin Wu*. (2024). A clinical predictive model for pre-transplantation Klebsiella pneumoniae colonization and relevance for clinical outcomes in patients receiving allogeneic hematopoietic stem cell transplantation. Microbiology spectrum, 12(2), e0203923. IF=3.700
5.Xiya Wei, Yingjun Chang, Xiaoyu Zhu, Xiaoxia Hu, Rong Guo, Yanming Zhang, Xiao Ma, Yue Han, Ying Wang, Huiying Qiu, Xiaojin Wu*, Depei Wu*. (2024). The impact of pre-transplant anti-HLA antibodies in transplants from HLA-identical sibling donors: A multicenter study. HLA, 103(1), e15286. IF=8.000
6.Wen-Qi Wu #, Yu-Qi Zhang #, Jie Xu #, Zai-Xiang Tang, Shi-Jia Li, Xi-Ya Wei, Ling Li, He-Qing Wu, Xiao Ma, Ji-Sheng Liu, De-Pei Wu*, Xiao-Jin Wu*. (2023). Risk Factors for Carbapenem-Resistant Enterobacteriaceae Colonization and the Effect on Clinical Outcomes and Prognosis in Allogeneic Hematopoietic Stem Cell Transplanted Patients. Infection and drug resistance, 16, 6821–6831. IF=3.900
7. Shijia Li#, Jianrong Ge#, Shiyuan Zhou, Wenjuan Zhu, Yue Han, Suning Chen, Shengli Xue, Ying Wang, Huiying Qiu, Xiaojin Wu*, Depei Wu*. (2023). CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr virus viremia after transplantation. Clinical and translational medicine, 13(10), e1459. IF=10.600
8. Xiedong Hong, Lang Tian, Qiong Wu, Liming Gu, Wenli Wang, Hanxu Wu, Mingxiao Zhao, Xiaojin Wu*, Chang Wang*. (2023). Plasma metabolomic signatures from patients following high-dose total body irradiation. Molecular omics, 19(6), 492–503. IF=2.900
9. Shiyuan Zhou #, Xiao Ma #, Chao Ma #, Qian Zhu, Qi Zhao, Ling Li, Shijia Li, Zaixiang Tang, Jun He, Depei Wu, Xiaojin Wu*, Songbing Qin*. (2023). Splenic irradiation combined with plasmapheresis and rituximab: a new option reducing donor-specific antibody in haploidentical hematopoietic stem cell transplantation. Bone marrow transplantation, 58(2), 226–228. IF=4.800
10.Shoubao Ma1, Tingting Tang1, Xiaojin Wu1, Anthony G Mansour, Ting Lu, Jianying Zhang, Li-Shu Wang, Michael A Caligiuri, Jianhua Yu. PDGF-D? PDGFRβ signaling enhances IL-15–mediated human natural killer cell survival[J]. Proceedings of the National Academy of Sciences, 2022, 119(3). IF=11.205
11. Xiya Wei, Yiyu Xie, Ruoyu Jiang, Huiyu Li, Heqing Wu, Yuqi Zhang, Ling Li, Shiyuan Zhou, Xiao Ma, Zaixiang Tang, Jun He, Depei Wu*, Xiaojin Wu*. (2022). The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world study. Frontiers in immunology, 13, 967026. IF=7.300
12. Ziyan Zhang #, Xiaojin Wu #, Meng Zhou #, Jiaqian Qi, Rui Zhang, Xueqian Li, Chang Wang, Changgeng Ruan *, Yue Han *. (2022). Plasma Metabolomics Identifies the Dysregulated Metabolic Profile of Primary Immune Thrombocytopenia (ITP) Based on GC-MS. Frontiers in pharmacology, 13, 845275. IF=5.600
13. Jianrong Ge #, Xiya Wei, Yanting Gu, Yiyu Xie, Huiyu Li, Shiyuan Zhou, Chenchen Liu, Shijia Li, Wenqi Wu, Jie Xu, Xiao Ma, Zaixiang Tang, Jun He, Depei Wu*, Xiaojin Wu*, Jisheng Liu*. (2022). Relationship of Oropharyngeal Colonization Microorganisms to Clinical Outcomes within 100 Days after Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and cellular therapy, 28(8), 496.e1–496.e7. IF=3.200
14.Yiyu Xie, Jay Parekh, Zaixiang Tang, Depei Wu, Xiaojin Wu. Donor-Specific Antibodies and Primary Graft Failure in Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis[J]. Transplantation and Cellular Therapy, 2021, 27(8): 687. e1-687. e7. IF=6.7
15. Bingyu Yang # , Xianfeng Zhang # , Huanle Gong # , Yuhui Huang , Chang Wang , Haiyan Liu , Chen Dong , Shoubao Ma , Xiaojin Wu* , Depei Wu*. High stearic acid diet modulates gut microbiota and aggravates acute graft-versus-host disease[J]. Signal transduction and targeted therapy, 2021, 6(1): 1-4. IF=18.187
16. Shanhao Tang, Yin Lu, Pisheng Zhang, Dong Chen, Xuhui Liu, Xiaohong Du, Junjie Cao, Peipei Ye, Lieguang Chen, Shuangyue Li, Keya Sha, Xian Xu Zhuang, Yiyu Xie, Xiaojin Wu *, Renzhi Pei *. (2021). Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma. Leukemia research, 110, 106710. IF=3.715
17. Ranran Zhao # ; Yiyu Xie # ; BingyuYang # ; ChangWang ; Qianlei Huang ; Yue Han ; LuluYang; ShuangYan ; XiaogangWang ; Chengcheng Fu * ; Depei Wu * ; Xiaojin Wu *; Identification of metabolic biomarkers to predict treatment outcome and disease progression in multiple myeloma. , American Journal of Cancer Research, 2020, 10(11): 3935-3946. IF=6.166
18. Zhengkui Zhang#, Xiuwu Fang#, Xiaojin Wu#, Li Ling, Feng Chu,Jingxian Li,Shuai Wang, Jia Zang, Bo Zhang,Sheng Ye, Long Zhang, Bing Yang,Shixian Lin, Huizhe Huang,Aijun Wang, Fangfang Zhou*Acetylation-Dependent Deubiquitinase OTUD3 Controls MAVS Activation in Innate Antiviral Immunity.Molecular Cell .2020,79, 304–319. IF=17.97
19. Jinge Xu #, Ranran Zhao #, Lulu Yang #, Huanle Gong, Shoubao Ma, Jia Chen, Hong Liu, Hongjie Shen, Mingqing Zhu, Suning Chen, Xiao Ma, Xiaojin Wu *, Depei Wu *. (2020). Haploidentical stem cells combined with a small dose of umbilical cord blood transplantation exert similar survival outcome of HLA-matched stem cells transplantation in T-cell acute lymphoblastic leukemia. Bone marrow transplantation, 55(6), 1197–1199. IF=5.483
20. Wenjuan,Dong # ; Xiaojin,Wu # ; Ma,Shoubao # ; Yufeng,Wang # ; Nalin, Ansel P; Zheng,Zhu ; Jianying,Zhang; Benson, Don M; Kai,He; Caligiuri, Michael A*; Jianhua,Yu * ; The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector, Cancer Discovery, 2019, 9(10): 1422-1437. IF=39.397
21. Xiaojin Wu#; Yiyu Xie#; Chang Wang#; Yue Han#; Xiebing Bao#;Shoubao Ma; Ahmet Yilmaz; Bingyu Yang; Yuhan Ji; Jinge Xu; Hong Liu; SuningChen; Jianying Zhang; Jianhua Yu*; Depei Wu*, Prediction of acute GVHD and relapse by metabolic biomarkers after allogeneic hematopoietic stem cell transplantation , JCI Insight, 2018, 3(9): e99672. IF=8.315
22. Bingyu Yang#; Chang Wang#; Yiyu Xie; Liangjing Xu; Xiaojin Wu*; Depei Wu*, Monitoring tyrosine kinase inhibitor therapeutic responses with a panel of metabolic biomarkers in chronic myeloid leukemia patients, Cancer Science, 2018, 109(3): 777~784. IF=6.716
23. Hongwei Wang#; Yibo Zhang#; Xiaojin Wu#; Yufeng Wang; Hanwei Cui; Xinxin Li; Jianying Zhang; Norman Tun; Yong Peng*; Jianhua Yu*, Regulation of Human Natural Killer Cell IFN-gamma Production by MicroRNA-146a via Targeting the NF-kappa B Signaling Pathway , Frontiers in Immunology, 2018, 9: 293. IF=7.561
24. Xiaojin Wu#,Yao Yao, Xiaojing Bao, Huifeng Zhou, Xiaowen Tang, Yue Han, Xiao Ma, Yuejun Liu, Jia Chen, Haixia Zhou, Song Jing, Bing Gu, Yang Xu,Aining Sun,Jun He*.Depei Wu *.KIR2DS4 and its variant KIR1D are associated with acute graft-versus-host Disease, cytomegalovirus, and overall survival after sibling-related HLA-matched transplantation in patients with donors with KIR gene haplotype. Biol Blood Marrow Transplant, 2016, 2(22):220-225. IF=5.742
25. Nana Wang# , Xiaojin Wu#, Guangying Sheng, Liang Ma, Lijun Wen, , Hong Yao, Suning Chen MLL-SEPT5 Fusion Transcript in Two de novo Acute Myeloid Leukemia Patients With t(11;22)(q23;q11). Ann Lab Med 2016;36:1-3. IF=3.464
26. Xiebing Bao#, Shengli Xue, Xiaohui Hu, Xiao Ma, Feng Chen, Suning Chen, Aining Sun, Depei Wu, Jianhua Yu, Xiaojin Wu*, Huiying Qiu*. Cytomegalovirus induces strong antileukemic effect in acute myeloid leukemia patients following sibling HSCT without ATG-containing regimen. Am J Transl Res, 2016, 8(2):653-661. IF=4.06
27. Xiaojin Wu#,Guangsheng He#, Yihua Fa#, Xiao Ma#, Depei Wu*, Huisheng Ai,Xiaojun Huang, Yue Han, Yang Xu,Aining Sun, Qian Wu, Xiaowen Tang, Zhengzheng Fu. Comparable outcomes of partially matched related and matched related allogeneic hematopoietic cell transplantation following reduced-intensity conditioning in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. International Journal of Hematology, 2013, 98:456-462. IF=2.49
28. Xiaojin Wu#, Ying Wang#,Yang Xu#, Depei Wu*,Aining Sun,Ziling Zhu, Yue Han,Huiying Qiu,Xiaowen Tang, Zhengzheng Fu,Guangsheng He, Caixia Li, Xiao Ma, Yuejun Liu. Cytomegalovirus Glycoprotein B Genotype in Hematopoietic Stem Cell Transplant Patients from China. Biol Blood Marrow Transplant, 2010,16(5):647-652. IF=5.742
29. XiaojinWu #, Jun He, Depei Wu *, Xiaojin Bao, Qiaocheng Qiu, Xiaoni Yuan, Yue Han, Aining Sun, Guanghua Chen, Yang Xu. KIR and HLA- Cw genotypes of donor-recipient pairs influence the rate of CMV reactivation following non-T-cell deleted unrelated donor hematopoietic cell transplantation. Am J Hematol, 2009, 84(11):776-777. IF=10.047


主持或参加科研项目（课题）及人才计划项目情况：
【在研项目】
1.国家自然科学基金面上项目， MIF-PRDX1信号调节NK细胞功能在AML中的作用及机制研究 82170222 2022-01至2025-12，55 万，主持，在研
2.江苏省自然科学基金面上项目 MIF-PRDX1信号调节NK细胞功能在AML中的作用及机制研究 BK20211070 2021-01至2024-12 10 万，主持，在研
3.国家重点研发计划资助 急性淋巴细胞白血病 2022YFC2502700 2022-01至2025-12 60万 骨干 在研
4.苏州市临床重点专项 脱敏方法治疗高致敏单倍体造血干细胞移植患者改善移植预后的临床和基础研究 2021-01至2024-12 30万 LCZX202101 主持 在研
5.苏州博习临床研究 BXL007 造血干细胞移植患者口咽部微生态菌群和病原菌定植菌去定植研究 30万 2023-01至2026-01 主持 在研
6.苏州博习领军人才 急性白血病T细胞免疫时空改变图谱 100万 主持 在研
7.国际研究项目 莱特莫韦预防CMV感染的真实世界研究 25万 主持 在研
8.苏州临床诊疗技术创新项目 复发难治恶性血液病的二次移植临床研究 200万 共同主持 在研
【已结题项目】
1.国家自然科学基金面上项目，81974001，高硬脂酸饮食通过增加肠道 Akkermansia mucinipila 丰度活化RORγt+ILC3 细胞促进 aGVHD 的机制研究，2020-01至2023-12，55 万，主持，在研
2.江苏省自然科学基金面上项目，BK20161204，过氧化物酶增殖激活受体在异基因造血干细胞移植后aGVHD中的调控作用，2016-07至2019-07，8万，已结题，在研
3.国家自然科学基金面上项目，81470346，Tim-3/gal-9信号通路介导Th17/Treg细胞 在造血干细胞移植后aGVHD中的调控作用研究，2014-01至2018-12，78万，已结题，参加
4.江苏省卫生厅项目，H201416，KIR2DS4基因及其变异体KIR1D对造血干细胞移植后巨细胞病毒激活的调控作用及其临床意义，2014-01至2016-12，2万，已结题，主持
5.国家青年自然科学基金，81100390，探讨激活性KIR在造血干细胞移植后早期CMV激活的调控作用的研究，2011-01至2013-12，20万元，已结题，主持
6.江苏省自然科学基金面上项目，BK2011265，异源性NK细胞在造血干细胞移植后早期CMV激活的调控作用，2011-01至2013-12，8万，已结题，主持

授权发明专利
1）吴德沛; 韩悦; 梁建英; 朱明清; 马骁; 吴小津; 陈峰; 仇惠英; 孙爱宁;
阮长耿, 地西他滨在治疗造血干细胞移植后血小板减少中的应用 , 2014.5.5, 中国, CN201410186295.6
2) 吴小津; 吴德沛; 王畅; 谢伊瑜; 韩悦; 马骁; 刘跃均; 顾斌, 硬脂酸/软脂酸组合作为aGVHD疾病诊断标志物的应用, 2021.08.10, 中国, CN107831225B
3） 吴德沛; 吴小津; 杨冰玉; 王畅; 韩悦; 马骁; 徐良静; 张翔, 肉豆蔻酸和甘油组合物在评估慢性粒细胞白血病TKI疗效的应用, 2020.11.24, 中国, CN


获得学术奖励
1. 2022-06，免疫治疗新技术在恶性血液病中的临床转化及推广应用，省人民政府，中国，省科技进步奖，一等奖，7/11
2. 2021-10，GC-MS代谢组学技术在血液病中的应用，江苏省卫生健康委员会，医学新技术引进奖，一等奖，1/3
3. 2018-12，移植相关性出凝血疾病及其相关机制，中华医学会，中国，医学科技奖，三等奖，3/8
4. 2018-12，移植相关性出凝血疾病及其相关机制，省医学会，中国，医学科技奖，一等奖，3/9